UK pushes space-made medicines from orbit to patients with new support package

The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis

NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production

Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy

The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences

MHRA warns of extremely rare vision risk linked to semaglutide

Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction

Savara resubmits FDA application for potential treatment in rare lung disease patients

The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer

UK’s healthcare regulator warns against dangerous online weight-loss drugs

Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy